Do You Suffer from Depression? New Combination of Ketamine & Rapamycin May Provide Relief
Please note: This trial has finished recruiting and is not accepting new participants.
Research Center: National Center for PTSD & Yale University
Location: VA Connecticut Healthcare System, 950 Campbell Ave, West Haven, CT
Lead Researcher: Dr. Chadi Abdallah
Ethics Committee: This study has been reviewed and approved by VA Connecticut Healthcare System Human Studies Subcommittee & Yale University Institutional Review Board Human Investigation Committee
Approximately 15 million Americans will experience depression every year. Unfortunately, current treatments available are not always effective in reducing symptoms of depression.
This research study is testing the effectiveness of a combination of medications in reducing symptoms of depression. These medications have already been approved by the FDA for a different use and have shown promise in reducing symptoms of depression.
This study seeks people who currently suffer from depression or bipolar disorder and have tried at least one antidepressant in the past with little to no symptom improvement. Participants are required to attend 9 study visits at the research site over 7 weeks and will be compensated up to $840 for participating in this study. Dependant on individual needs, participants may be reimbursed for mileage, be provided with cab/train/airfare up front, and/or be provided a hotel stay to be able to attend study visits.
Benefits to Participation
- You may experience an improvement in your depression symptoms.
- You will receive a thorough medical and psychiatric evaluation at no cost to you.
- You will be compensated up to $840 for participating in this study.
- You will be helping to advance medical research aimed at improving treatments for depression.
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time. Your decision to participate (or not), or to withdraw will not impact your medical or mental health care benefits in anyway.
- Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law, and will not impact your benefits or access to care in anyway.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Men and women aged between 21 – 65 years old who suffer from depression or bipolar disorder
- Have tried at least one antidepressant in the past and found that it did not completely resolve symptoms
- Able to attend 9 study visits at the research site over 7 weeks including:
- (1) Initial Screening – 5 hours
- (1) Baseline visit – 5 hours
- (2) Infusion visits – 6 hours, each
- (2) 24 hour post infusion visits – 5 hours
- (3) Weekly follow up visits – 2 hours